DOCSLIB.ORG

Opportunities for Use of One Species for Longer-Term Toxicology Testing During Drug Development a Cross-Industry Evaluation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Opportunities for Use of One Species for Longer-Term Toxicology Testing During Drug Development a Cross-Industry Evaluation Regulatory Toxicology and Pharmacology 113 (2020) 104624 Contents lists available at ScienceDirect Regulatory Toxicology and Pharmacology journal homepage: www.elsevier.com/locate/yrtph Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation T ∗ Helen Priora, , Paul Baldrickb, Sonja Bekenc, Helen Boolerd, Nancy Bowere, Paul Brookerf, Paul Browng, Brian Burlinsonh, Leigh Ann Burns-Naasi, Warren Caseyj, Melissa Chapmank, David Clarkel, Lolke de Haanm, Olaf Doehrn, Noel Downeso, Meghan Flahertyp, Nichola Gellatlya, Sophia Gry Moesgaardq, Jennifer Harrisr, Mark Holbrooks, Julia Huit, David Jonesu, Keith Jonesv, Hilla Kedarw, Andreas Mahlx, Alli Mannineny, Aidan McGuirez, Elisabeth Mortimer-Cassenaa, Marjorie Perazaab, Michael K. Pugsleyac, Jacques Richardad, Ruth Robertsae, Wendy Roosenaf, Andreas Rothfussag, Ankie Schoenmakersah, Fiona Sewella, Richard Weaverai, Lucinda Weiraj, Alison Wolfreysak, Ian Kimberal a National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), Gibbs Building, 215 Euston Road, London, NW1 2BE, UK b Covance Laboratories Ltd, Otley Road, Harrogate, HG3 1PY, UK c Federal Agency for Medicines and Health Products (FAMHP), Victor Hortaplace 40/40, Brussels, 1060, Belgium d Genentech, Inc, 1 DNA Way, South San Francisco, CA, 94080, USA e Eisai Inc, 155 Tice Blvd, Woodcliff Lake, NJ, 07677, USA f Board member, NC3Rs, Gibbs Building, 215 Euston Road, London, NW1 2BE, UK g Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA h Covance, Huntingdon, Cambridgeshire, PE28 4HS, UK i Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, 94404, USA j National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), National Institute of Environmental Health Sciences, P.O. Box 12233, Research Triangle Park, NC, 27709, USA k Oncology Safety, Clinical Pharmacology and Safety Sciences,R&D, AstraZeneca, Cambridge, UK l Lilly Research Laboratories, Indianapolis, IN, 46285, USA m Biologics and Advanced Therapeutics Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK n Bayer Pharma AG, Müllerstrasse 170, 13353, Berlin, Germany o Sequani Limited, Bromyard Rd, Ledbury, Herefordshire, HR8 1LH, UK p Takeda Pharmaceuticals, 300 Massachusetts Ave, Cambridge, MA, 02139, USA q Novo Nordisk A/S, Novo Nordisk Park, Maaloev, Denmark r Association of British Pharmaceutical Industry (ABPI), 105 Victoria Street, London, SW1E 6QT, UK s VAST Pharma Solutions Ltd, Harrogate, UK t Celgene, 86 Morris Avenue, Summit, NJ, 07901, USA u Medicines Healthcare products Regulatory Agency (MHRA) 10 South Colonnade, Canary Wharf, London, E14 4PU, UK v CFMD Ltd, Peterborough, UK w Teva Pharmaceuticals, Netanya Area, Israel x Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland y Prekliniska Byran Sweden AB, Stockholm, Sweden z Charles River Laboratories, Preclinical Services, Tranent, Edinburgh, EH33 2NE, UK aa Regulatory Safety Centre of Excellence, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK ab Pfizer Drug Safety Research and Development, 300 Technology Square, Cambridge, MA, 02139, USA ac Cytokinetics, South San Francisco, CA, 94080, USA ad Sanofi, 371 Rue du Professeur Blayac, Montpellier, 34000, France ae ApconiX, Alderley Park, Alderley Edge, Cheshire, SK10 4TG, UK af Janssen Research & Development, Turnhoutseweg 30, 2340, Beerse, Belgium ag Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, CH - 4070, Basel, Switzerland ah Charles River Laboratories, Den Bosch B.V, the Netherlands ai Institut de Recherches Internationales Servier, Biopharmacy, 92284, Suresnes, Cedex, France Abbreviations: ADC, Antibody-drug conjugate; ABPI, Association of the British Pharmaceutical Industry; CRO, contract research organisation; EU, European Union; FIH, first-in-human; GLP, Good Laboratory Practice; ICH, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; IND, Investigational New Drug; mAbs, monoclonal antibodies; NC3Rs, National Centre for the Replacement, Refinement and Reduction of Animals in Research; NHP, non-human primate ∗ Corresponding author. Gibbs Building, 215 Euston Rd, London, NW1 2BE, UK. E-mail address: [email protected] (H. Prior). https://doi.org/10.1016/j.yrtph.2020.104624 Available online 29 February 2020 0273-2300/ © 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/). H. Prior, et al. Regulatory Toxicology and Pharmacology 113 (2020) 104624 aj GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 0DP, UK ak UCB Biopharma, Bath Rd, Slough, SL1 3WE, UK al University of Manchester, Faculty of Biology, Medicine and Health, Oxford Rd, Manchester, M13 9PL, UK ARTICLE INFO ABSTRACT Keywords: An international expert working group representing 37 organisations (pharmaceutical/biotechnology compa- 3Rs nies, contract research organisations, academic institutions and regulatory bodies) collaborated in a data sharing Biologics exercise to evaluate the utility of two species within regulatory general toxicology studies. Anonymised data on Drug development 172 drug candidates (92 small molecules, 46 monoclonal antibodies, 15 recombinant proteins, 13 synthetic ICHS6(R1) peptides and 6 antibody-drug conjugates) were submitted by 18 organisations. The use of one or two species Nonclinical across molecule types, the frequency for reduction to a single species within the package of general toxicology Non-rodent fi Rodent studies, and a comparison of target organ toxicities identi ed in each species in both short and longer-term Small molecules studies were determined. Reduction to a single species for longer-term toxicity studies, as used for the devel- Species selection opment of biologicals (ICHS6(R1) guideline) was only applied for 8/133 drug candidates, but might have been Toxicology possible for more, regardless of drug modality, as similar target organ toxicity profiles were identified in the short-term studies. However, definition and harmonisation around the criteria for similarity of toxicity profiles is needed to enable wider consideration of these principles. Analysis of a more robust dataset would be required to provide clear, evidence-based recommendations for expansion of these principles to small molecules or other modalities where two species toxicity testing is currently recommended. 1. Introduction different approaches to safety assessment can enhance predictivity, as well as reduce animal use through efficiency improvements or The biopharmaceutical industry recognises the importance of an streamlined processes. This may include a requirement for fewer stu- ongoing review of the regulatory recommendations for the nonclinical dies, fewer animals per study or shortened timelines to reach decision- safety assessment of new investigative drugs. There is a responsibility to making milestones. Arguably, such reviews are conducted most effec- ensure human safety and that individual nonclinical studies and overall tively when pharmaceutical companies work together to share data and safety strategies reflect advances in the scientific field, such as em- experience, in concert with regulatory authorities, for example as ploying new technologies (e.g., in silico and in vitro approaches), and the contributors to working parties and industry consortia. Recently, con- growing application of mechanistic toxicology to understand molecular sortia have reviewed topics such as nonclinical to clinical data trans- pathways underlying toxic effects. This can also lead to opportunities to lation (Monticello et al., 2017), the effectiveness of nonclinical strate- replace, refine and reduce (the 3Rs) the use of laboratory animals when gies in support of safe clinical trials (Butler et al., 2017), in silico appropriate. Review of best practices and identification of new and/or prediction of toxicities (Briggs et al., 2015) and the most appropriate Table 1 Relevant extracts from ICH general guidance regarding the species required for general toxicology studies. ICHM3(R2): Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals 5. Repeated dose toxicity studies. In principle, the duration of the animal toxicity studies conducted in two mammalian species (one non-rodent) should be equal to or exceed the duration of the human clinical trials up to the maximum recommended duration of the repeated-dose toxicity studies. Recommended Non-clinical Studies to Support Exploratory Clinical Trials. Approaches 1 and 2 describe requirements for a toxicity study in one species, usually rodent ICHS6(R1): Pre-clinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals 3.3 Animal Species/Model Selection. Safety evaluation programs should include the use of relevant species. A relevant species is one in which the test material is pharmacologically active due to the expression of the receptor or an epitope (in the case of monoclonal antibodies). Safety evaluation programs should normally include two relevant species. However, in certain justified cases one relevant species may suffice (e.g., when only one relevant species can be identified or where the biological activity of the biopharmaceutical is well understood). In addition, even where two species may be necessary to characterise toxicity
Load more

Recommended publications
  • Annual Meeting and Toxexpo™ TT RANSPARENT RR ELIABLE UU NSURPASSED QUALITY SS ATISFACTION TT IMELY Your Leading Partner for Preclinical Research
    Directory Baltimore, Maryland March 12–16, 2017 56th Annual Meeting and ToxExpo™ TT RANSPARENT RR ELIABLE UU NSURPASSED QUALITY SS ATISFACTION TT IMELY Your Leading Partner for Preclinical Research • Molecular Imaging • Radiochemistry • Luminescence • in vivo, in vitro • Fluorescence • X-Ray, MicroCT • Biomarker Assessment • LC-MS/MS, Multiplex • GLP Toxicology • Acute, subchronic, chronic • PK/PD • ELISA • Histology • Flow Cytometry • Cryo- and Paraffin sections • Safety Pharmacology • Histopathology • Immunohistochemistry • Bioanalytical Chemistry Offices in USA Europe Australia +1 717-798-9990 +49 89 122 287 690 +61 3 9988 1800 [email protected] Booth 2046 AAALAC accredited GLP- compliant Directory SOT Mobile Event App! ToxExpo Hours Access information from the SOT Program, The Monday, March 13 9:15 AM to 4:30 PM Toxicologist, and ToxExpo Directory via your mobile device. Tuesday, March 14 9:15 AM to 4:30 PM Wednesday, March 15 9:15 AM to 4:30 PM Table of Contents Supporters .............................................................................. 2 Exhibit Hall Map ................................................................... 4 2017 Exhibitors ...................................................................... 6 General Information ..........................................................10 Exhibitor-Hosted Sessions ..............................................14 Exhibitor Descriptions .....................................................24 Exhibitor Product/Service Category Listing ........ 128 ToxExpo.com Available
    [Show full text]
  • CONTRACT RESEARCH ORGANIZATIONS (Cros) in ASIA 2014
    CONTRACT RESEARCH ORGANIZATIONS (CROs) in ASIA 2014 Pacific Bridge Medical 7315 Wisconsin Avenue, Suite 609E Bethesda, MD 20814 (301) 469-3400 (301) 469-3409 Email: [email protected] Copyright © 2014 Pacific Bridge Medical. All rights reserved. This content is protected by US and International copyright laws and may not be copied, reprinted, published, translated, resold, hosted, or otherwise distributed by any means without explicit permission. Disclaimer: the information contained in this report is the opinion of Pacific Bridge Medical, a subsidiary of Pacific Bridge, Inc. It is provided for general information purposes only, and does not constitute professional advice. We believe the contents to be true and accurate at the date of writing but can give no assurances or warranties regarding the accuracy, currency, or applicability of any of the contents in relation to specific situations and particular circumstances. TABLE OF CONTENTS CONDUCTING CLINICAL TRIALS IN ASIA ................................................................................ 1 WHY GO TO ASIAN CROS? ..................................................................................................... 1 WHAT TO WATCH OUT FOR .................................................................................................... 2 HOW TO CHOOSE A CRO ......................................................................................................... 3 WHICH COUNTRIES? ...............................................................................................................
    [Show full text]
  • Introduction to Safety Pharmacology
    What is Safety Pharmacology? 2 What is Safety Pharmacology? Safety pharmacology is a branch of pharmacology specializing in detecting and investigating potential undesirable pharmacodynamic effects of new chemical entities (NCEs) on physiological functions in relation to exposure in the therapeutic range and above. Safety pharmacology studies are required to be completed prior to human exposure (i.e., Phase I clinical trials), and regulatory guidance is provided in ICH S7A and other documents. Key Concepts of Safety Pharmacology 4 Systems Primary organ systems (so-called core battery systems) are: • Central Nervous System • Cardiovascular System • Respiratory System Secondary organ systems of interest are: • Gastrointestinal System • Renal System Key aims of safety pharmacology The aims of nonclinical safety pharmacology evaluations are: • To protect Phase I clinical trial volunteers from acute adverse effects of drugs • To protect patients (including patients participating in Phase II and III clinical trials) • To minimize risks of failure during drug development and post-marketing phases due to undesirable pharmacodynamic effects The following key issues have to be considered within safety pharmacology: • The detection of adverse effects liability (hazard identification) • Investigation of the mechanism of effect (risk assessment) • Mitigation strategies (risk management) • Calculating a projected safety margin • Implications for clinical safety monitoring 7 Pharmacology vs. Toxicology? Pharmacology - the study of the action of xenobiotics,
    [Show full text]
  • Baldrick-Biosimilar-2017.Pdf
    Regulatory Toxicology and Pharmacology 86 (2017) 386e391 Contents lists available at ScienceDirect Regulatory Toxicology and Pharmacology journal homepage: www.elsevier.com/locate/yrtph Pharmacokinetic and toxicology comparator testing of biosimilar drugs e Assessing need * Paul Baldrick, PhD Professor, Executive Director, Regulatory Strategy Covance Laboratories Ltd., Otley Road, Harrogate, HG3 1PY, North Yorkshire, United Kingdom article info abstract Article history: A key element in the development of a biosimilar molecule is the comparability of the biological activity/ Received 24 January 2017 nonclinical similarity to the innovator drug. Although some regulatory guidelines are encouraging little Received in revised form or no in vivo testing, currently a common practice is to perform at least one toxicology and/or one 15 April 2017 pharmacokinetic (PK) study to assess if any different findings occur for in-life, clinical pathology and Accepted 18 April 2017 histopathological parameters or in exposure. An exercise was performed in which the results of such Available online 20 April 2017 testing were evaluated. It was found that 10 PK comparison studies in the cynomolgus monkey across 4 monoclonal (Mab) classes showed similar exposure in all cases. In 17 toxicology comparison studies with Keywords: Biosimilar 5 Mab classes performed in the same species and in 7 toxicology comparison studies with non-Mab fi Innovator biosimilars in the rat, no new/unexpected ndings were seen and drug exposure measurement gave Pharmacokinetic testing comparable values in all cases. Overall, although this work does not rule out possible utility of some Toxicology testing in vivo testing (notably in the form of stand-alone PK testing) to confirm similar exposure between the 2 Comparability exercise molecules tested, it is unclear what benefit can be gained from toxicology testing, especially if compa- Regulatory guidance rability has been demonstrated from physiochemical and in vitro characterisation.
    [Show full text]
  • Guidance for Industry, Investigators, and Reviewers: Exploratory IND
    Guidance for Industry, Investigators, and Reviewers Exploratory IND Studies U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) January 2006 Pharmacology/Toxicology G:\7086fnl.doc 12/29/05 Contains Nonbinding Recommendations Guidance for Industry, Investigators, and Reviewers Exploratory IND Studies Office of Training and Communication Division of Drug Information, HFD-240 Center for Drug Evaluation and Research Food and Drug Administration 5600 Fishers Lane Rockville, MD 20857 (Tel) 301-827-4573 http://www.fda.gov/cder/guidance/index.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) January 2006 Pharmacology/Toxicology Contains Nonbinding Recommendations TABLE OF CONTENTS I. INTRODUCTION............................................................................................................. 1 II. BACKGROUND ............................................................................................................... 2 A. Traditional Phase 1 Approach......................................................................................................2 B. Exploratory IND Approach ..........................................................................................................3 III. CONTENT OF IND SUBMISSIONS ............................................................................. 5 A. Clinical Information ......................................................................................................................5
    [Show full text]
  • Handbook Non-Clinical Safety Testing
    UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) HANDBOOK NON-CLINICAL SAFETY TESTING This Handbook on Non-clinical Safety Testing is designed to serve as an aid for scientists who wish to undertake non-clinical safety testing for regulatory purposes during product development. It has been developed as part of a significant and wide- ranging technology transfer and capacity building programme in the area of pre-clin- ical product development for disease endemic countries. The Non-clinical Safety Testing Handbook was produced by a Scientific Working Group (SWG) on pre-clinical issues, convened by the UNICEF/UNDP/World Bank/WHO Special Programme for Research & Training in Tropical Diseases (TDR) and consisting of independent scientific specialists from around the world. The Handbook is broadly based on current safety testing guidelines including those of the Organisation for Eco- nomic Cooperation and Development (OECD) and the International Conference on Harmonisation (ICH). The Handbook will provide scientists and laboratories in disease endemic countries with the necessary technical aid for planning and implementing non-clinical safety testing programmes. The Handbook attempts to highlight the differences between syn- thetic chemical drug, vaccine and traditional herbal (botanical) medicine development programmes. TDR gratefully acknowledges the participation and support of all those involved in the production of this Handbook. For all correspondence: Dr Deborah Kioy Pre-clinical Coordinator Product Research and Development TDR/WHO Avenue Appia 20 1211 Geneva 27 – Switzerland Tel: +41 22 791 3524 Fax: +41 22 791 4854 E-mail: [email protected] TABLE OF CONTENTS FOREWORD .
    [Show full text]
  • Regulatory Toxicology
    Regulatory Toxicology Regulatory (Pharmaceutical) Toxicology Ruth Roberts Director, ApconiX Ltd Chair of Drug Discovery, University of Birmingham, UK Conflict of Interest Declaration Ruth Roberts is co-founder and co-director of Apconix, an integrated toxicology and ion channel research company that provides expert advice on nonclinical aspects of drug discovery and drug development to academia, industry, government and not-for-profit organisations. Overview/Objectives • Outline and purpose of regulatory • Outline of general toxicology testing toxicology testing for pharmaceuticals for agrochemicals and general • Overall design of the package from first time chemicals in humans (FTIH) through to marketing authorisation • Challenges and opportunities • Translation • Purpose: ensuring volunteer and patient safety in clinical trials • Attrition • Assumptions to challenge • Decision making • In vitro replacements • General Toxicology • Future Perspectives • Maximum tolerated dose (MTD)/Dose Range Finding (DRFs), “pivotal” and chronic toxicology studies • Design (doses, species, duration) and outcome • Regulatory documentation Regulatory Toxicology: Learning Objectives • Understand the purpose of pharmaceutical toxicology • Understand the pivotal role played by general toxicology studies in protecting volunteer and patient safety • Understand common principles with other sectors (agrochemicals, general chemicals) • Understand outcome of general toxicology studies and the principles and caveats of their designs • Understand the global framework
    [Show full text]
  • Drug Developement
    DRUG DEVELOPEMENT 2 Summary Acronyms used in preclinical development Life cycle of medicine Clinical trials for Beginners The Funnel Road map Example of drug development: Chemical level Pharmaceutical level Preclinical pharmacology Preclinical Toxicology Preclinical ADME 3 Preclinical development acronyms (1) ADME Absorption, distribution, metabolism, and excretion API Active pharmaceutical ingredient: any component intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease. CFR Code of Federal Regulations CGMP, GMP (Current) good manufacturing practice CMC Chemistry manufacturing and controls CoA Certificate of analysis CRO Contract research organization CTM Clinical trial material Cmax Maximum plasma concentration 4 Preclinical development acronyms (2) DP Drug product: finished dosage form (for example, tablet, capsule, solution) that contains an active drug ingredient, generally in association with inactive ingredients DS Drug substance: any substance that is represented for use in a drug and that, when used in manufacturing, processing, or packaging of a drug, becomes an active ingredient or a finished drug form FDA US Food and Drug Administration FIH First in human FRS Foreign related substances GLP Good laboratory practice HPLC High performance liquid chromatography ICH International Conference on Harmonization IND Investigational New Drug application MTD Maximum tolerated dose NCE New chemical entity 5 Preclinical development acronyms (3) NDA New drug
    [Show full text]
  • Bioanalytical Systems, Inc
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) _ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended September 30, 2020. OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ___________ to _____________. Commission File Number 000-23357 BIOANALYTICAL SYSTEMS, INC. (Exact name of the registrant as specified in its charter) INDIANA 35-1345024 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 2701 KENT AVENUE WEST LAFAYETTE, INDIANA 47906 (Address of principal executive offices) (Zip code) (765) 463-4527 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbols Name of exchange on which registered Common Shares BASi NASDAQ Capital Market Securities registered pursuant to section 12(g) of the Act: None Indicate by checkmark if the registrant is a well-known seasoned issuer, as defined by Rule 405 of the Securities Act. YES NO _ Indicate by checkmark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES NO _ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Recent Efforts to Elucidate the Scientific Validity of Animal-Based
    Bailey and Balls BMC Medical Ethics (2019) 20:16 https://doi.org/10.1186/s12910-019-0352-3 DEBATE Open Access Recent efforts to elucidate the scientific validity of animal-based drug tests by the pharmaceutical industry, pro-testing lobby groups, and animal welfare organisations Jarrod Bailey1* and Michael Balls2 Abstract Background: Even after several decades of human drug development, there remains an absence of published, substantial, comprehensive data to validate the use of animals in preclinical drug testing, and to point to their predictive nature with regard to human safety/toxicity and efficacy. Two recent papers, authored by pharmaceutical industry scientists, added to the few substantive publications that exist. In this brief article, we discuss both these papers, as well as our own series of three papers on the subject, and also various views and criticisms of lobby groups that advocate the animal testing of new drugs. Main text: We argue that there still remains no published evidence to support the current regulatory paradigm of animal testing in supporting safe entry to clinical trials. In fact, the data in these recent studies, as well as in our own studies, support the contention that tests on rodents, dogs and monkeys provide next to no evidential weight to the probability of there being a lack of human toxicity, when there is no apparent toxicity in the animals. Conclusion: Based on these data, and in particular on this finding, it must be concluded that animal drug tests are therefore not fit for their stated purpose. At the very least, it is now incumbent on—and we very much encourage—the pharmaceutical industry and its regulators to commission, conduct and/or facilitate further independent studies involving the use of substantial proprietary data.
    [Show full text]
  • In Silico and in Vitro Testing Resources Alcyomics, Ltd., Offers In
    In Silico and In Vitro Testing Resources Alcyomics, Ltd., offers in vitro human-based pre-clinical drug safety testing. It manufactures SkimuneTM (human skin explants for safety and efficacy testing) and offers immunogenicity services, efficacy testing of immunomodulators, hypersensitivity testing, potency assessment, cellular and cytokine assays and safety assessment services. AllCells, LLC, offers more than 150 primary cell types and related RNA and cDNA from normal and disease-state tissues.Cell types include stem cells (progenitor, CD34+, etc.), hematopoietic, human hematologic disease, endothelial, dendritic, HUVEC cells and many others. It also offers services such as drug discovery, device validation, flow cytometry and cell sorting, tissue culture protein analysis and genotyping as well as stem cell and immune assays. Alternative Toxicity Services offers high-content screening for evidence-based acute general toxicity and neurotoxicity. APSciences, Inc., offers Integrated Discrete Multiple Organ Co-culture (IdMOC) technology, which is an in vitro model consisting of multiple, inner wells within a larger interconnecting chamber. It is based on the concept that the multiple organs in a human (or other animal) are physically separated but interconnected by the systemic circulation (i.e., blood). IdMOC can be used to evaluate drug toxicity, drug metabolism and drug distribution as well as anti-cancer drugs for cytotoxicity, efficacy and mechanism of action. Asterand, PLC, provides high quality, well characterised human tissue through its worldwide network of 75 active collaborative donor institutions and human tissue-based research solutions to drug discovery scientists. It also provides a collaborative scientific approach to deliver human tissue-based data ontarget and biomarker validationas well ascompound potency, effect and safety.
    [Show full text]
  • Toxexpo Directory
    ToxExpoTM Directory 54th Annual Meeting & ToxExpoTM March 22–26, 2015 San Diego Convention Center San Diego, California TRANSLATING DISCOVERIES Reaching the clinic can be a daunting task. Let the experts at Charles River be your guide, every step of the way. Our expansive safety assessment portfolio is supported by advanced imaging and biomarker services that provide a deep scientific understanding of your compound and produce the high quality data you need to optimize your drug development program. Visit us at booth 1326 to learn more. every step of the way. www.criver.com/SOT2015 ToxExpo Directory Table of Contents ToxExpo Exhibit Hall Hours Supporters .......................................................................... 2 Monday, March 23 9:00 AM–4:30 PM Exhibit Hall Map ...............................................................4 2015 Exhibitors ..................................................................6 Tuesday, March 24 8:30 AM–4:30 PM General Information ....................................................... 10 Wednesday, March 25 8:30 AM–4:30 PM Exhibitor-Hosted Sessions ...........................................14 Exhibitor Descriptions ..................................................22 Exhibitor Product/Service Category Listing ....... 136 Follow us on Twitter at @ToxExpo and @SOToxicology Recording, Photography, and Cell Phone Policy SOT Badge Policy—altering of SOT badges in any way is strictly prohibited. All attendees must be officially registered • Photographing exhibit booths is prohibited. for the
    [Show full text]